Plain-English translation of NCT07128797 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and effective for treating non-alcoholic fatty liver disease (fatty buildup in the liver not caused by alcohol). Participants will receive either or a placebo (inactive injection) as shots under the skin at different doses and schedules. The study will track how your body handles the medication and whether it helps reduce liver fat.
Many people develop fatty liver disease related to weight, diabetes, or high cholesterol, and it can progress to serious liver damage. This trial is exploring whether this new treatment might help slow or reverse fatty liver disease before it becomes more severe.
You likely qualify if…
You likely don't qualify if…
If you are selected, you will receive injections of either or a placebo under your skin either once a week or once every two weeks, depending on which group you are assigned to. You will visit the clinic multiple times for blood tests, imaging scans, and check-ups to monitor how the medication is working and whether you experience any side effects. The trial involves about 32 participants total across multiple centers, and your participation will help doctors understand whether this new treatment is safe and could help people with fatty liver disease.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China